Syneos Health to Present at Upcoming Investor Conferences
MORRISVILLE, N.C., May 21, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, announced that the Company is scheduled to present at two upcoming investor conferences:
- Chief Executive Officer Alistair Macdonald is scheduled to present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 8:30 a.m. ET.
- Chief Financial Officer Jason Meggs is scheduled to present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021, at 3:00 p.m. ET.
A live webcast of each event, along with a link to the presentation materials and archived audio replay of each presentation, will be available on the Company’s Investor Relations website at investor.syneoshealth.com.
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 25,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
|Investor Relations Contact:||Press/Media Contact:|
|Ronnie Speight||Gary Gatyas|
|Senior Vice President, Investor Relations||Executive Director, External Communications|
|+1 919 745 2745||+1 908 763 3428|
Upcoming Life Sciences Events
- June 2021
- Seoul: BIO Korea
- BIO Digital
- BioTrinity 2021
Latest company news
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia